1. 873PSafety and tolerability of atezolizumab (atezo) plus bevacizumab (bev) vs sunitinib (sun) in untreated metastatic renal cell carcinoma (mRCC): Pooled analysis of IMmotion150 and IMmotion151. (23rd October 2018) Authors: Suarez, C; Choueiri, T K; McDermott, D F; Escudier, B; Atkins, M B; Powles, T B; Rini, B I; Motzer, R J; Pal, S K; Fong, L; De Giorgi, U; Wang, Y; Khaznadar, T; Di Nucci, F; Kaiser, C; Tayama, D; Donskov, F Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. LBA31Molecular correlates differentiate response to atezolizumab (atezo) + bevacizumab (bev) vs sunitinib (sun): Results from a phase III study (IMmotion151) in untreated metastatic renal cell carcinoma (mRCC). (23rd October 2018) Authors: Rini, B I; Huseni, M; Atkins, M B; McDermott, D F; Powles, T B; Escudier, B; Banchereau, R; Liu, L-F; Leng, N; Fan, J; Doss, J; Nalle, S; Carroll, S; Li, S; Schiff, C; Green, M; Motzer, R J Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗